Taking Subvisible Particle Quantitation to the Limit: Uncertainties and Statistical Challenges With Ophthalmic Products for Intravitreal Injection.

analysis antibody drugs biopharmaceutical characterization degradation products developability injectables microparticles monoclonal antibodies ophthalmic drug delivery protein aggregation

Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
01 2020
Historique:
received: 26 07 2019
revised: 30 10 2019
accepted: 30 10 2019
pubmed: 5 11 2019
medline: 23 3 2021
entrez: 5 11 2019
Statut: ppublish

Résumé

Subvisible particles are a critical quality attribute of pharmaceutical products. The reliability of particle quantitation increases with the number of particles in the analyzed sample volume. However, for analyses of low-volume drug products, such as ophthalmic products for intravitreal injection or biopharmaceuticals in general, sample volumes as small as possible should be used to avoid pooling and consequently, the contamination with foreign particles. The aim of our study was to evaluate the variability of particle concentrations obtained by light obscuration measurements to define the minimum required analyzed sample volume to achieve statistically meaningful results by using conditions that are practically feasible. Statistical evaluation suggests that for particle concentrations close to a predefined limit, large sample volumes (a multiple of typical intravitreal product volumes) would be required for a high probability to correctly classify samples with respect to the predefined limit. Below a minimum analyzed volume, even a measurement result of 0 particles does not allow to conclude compliance with the respective particle concentration limit with sufficient certainty. A small analyzed volume could be justified as long as the measurement uncertainty remains acceptable compared with the predefined limit.

Identifiants

pubmed: 31682829
pii: S0022-3549(19)30733-6
doi: 10.1016/j.xphs.2019.10.061
pii:
doi:

Substances chimiques

Ophthalmic Solutions 0
Pharmaceutical Preparations 0
Polystyrenes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

505-514

Informations de copyright

Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Auteurs

Marina Gühlke (M)

Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.

Johanna Hecht (J)

Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.

Armin Böhrer (A)

Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.

Andrea Hawe (A)

Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany.

Felix Nikels (F)

Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.

Patrick Garidel (P)

Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.

Tim Menzen (T)

Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany. Electronic address: Tim.Menzen@coriolis-pharma.com.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs
Humans Meta-Analysis as Topic Sample Size Models, Statistical Computer Simulation
1.00
Humans Personality Judgment Choice Behavior Male

Classifications MeSH